Advertisement
News
Advertisement

FDA grants study of Abiomed heart device

Mon, 12/06/2010 - 8:34am
Mass High Tech: The Journal of New England Technology

Cardiac medical device maker Abiomed Inc. has won conditional approval from the U.S. Food and Drug Administration for a pilot study to test its Impella 2.5 device reducing heart muscle damage in patients with ST-elevation myocardial infarction (STEMI).

The study, called MINI-AMI, will look at whether using the Impella 2.5 heart pump for 24 hours after percutaneous intervention helps to reduce the blockage of blood flow, as compared to standard procedures post-percutaneous intervention.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading